News & Views

  • Biophytis completes a EUR two million B round financing

Biophytis completes a EUR two million B round financing

Oct 15 2012 Read 1459 Times

Biophytis, a research company in health and nutrition focusing on metabolic disorders and age-related diseases, has raised EUR two million (US$2.6M) in B round financing. Metabrain Research, a spin-off of Merck Serono based in Chilly-Mazarin (south of Paris) joined existing investors Seventure partners and CM-CIC Capital Prive in this round.

Biophytis is leading two projects in collaboration with Metabrain Research; the first to target treatment of sarcopenic obesity (SARCOB), in partnership with the Myology Institute and Institute of Cardio-metabolism and Nutrition, both at the University of Pierre and Marie Curie (UPMC), and France’s national agricultural research institute, INRA. A second project, MACULIA, focusing on treating age-related macular degeneration, involves collaboration with UPMC’s Institut de la Vision and Iris Pharma, a contract research organisation dedicated to ophthalmology. The projects are sponsored by the Medicen competitivity cluster in the Paris region which benefit from grants of EUR 2.3 million from a number of European and French local and national government bodies.

“The arrival of Metabrain Research as a shareholder marks a step change in a partnership that we have pursued for several years in the SARCOB project,” said Stanislas Veillet, CEO and founder of Biophytis. “It will reinforce our capacity to develop drug candidates derived from our portfolio of nutraceutical active substances, with the aim of signing co-development contracts with pharmaceutical companies.”

“The worldwide market of nutrition, where food and drugs meet, has already reached EUR 120 billion annual revenues and is growing at ten per cent a year,” said Isabelle de Cremoux, general manager at Seventure partners. “This makes it very attractive to many industry players. Biophytis is a pioneer in this field and this financing will allow it to accelerate its development with a strategy targeting both drugs and nutrition.”

The French and European organisations that are providing grants to the SARCOB and MACULIA projects are FUI (Fonds Unique Interministeriel, a cross-ministry funding body), the European Regional Development Fund, the Essonne and Seine-Saint-Denis departments, the Ile de France region and the city of Paris.


 

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Labmate UK & Ireland September 2020

September 2020

In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...

View all digital editions